CG Oncology (NASDAQ:CGON) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research note released on Tuesday, Benzinga reports. The firm currently has a $75.00 price objective on the stock.

A number of other brokerages have also commented on CGON. Bank of America assumed coverage on CG Oncology in a research note on Friday, June 28th. They set a buy rating and a $65.00 price target for the company. Roth Capital upgraded CG Oncology to a strong-buy rating in a research report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on shares of CG Oncology in a report on Tuesday, August 27th. They issued a buy rating and a $65.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of Buy and an average price target of $64.17.

CG Oncology Price Performance

CGON stock opened at $39.00 on Tuesday. The company’s fifty day moving average price is $35.29 and its 200-day moving average price is $35.37. CG Oncology has a one year low of $25.77 and a one year high of $50.23.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.14. The company had revenue of $0.11 million during the quarter. As a group, analysts anticipate that CG Oncology will post -1.47 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Hong Fang Song sold 650,455 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the transaction, the director now owns 586,982 shares of the company’s stock, valued at approximately $20,755,683.52. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in shares of CG Oncology in the 1st quarter worth about $492,000. Capstone Investment Advisors LLC bought a new stake in CG Oncology in the first quarter worth about $806,000. TimesSquare Capital Management LLC bought a new stake in CG Oncology in the first quarter worth about $9,837,000. Vanguard Group Inc. purchased a new position in shares of CG Oncology during the first quarter valued at approximately $97,678,000. Finally, Ameritas Investment Partners Inc. bought a new position in shares of CG Oncology during the first quarter valued at approximately $102,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.